Stock Analiz

Endovia Health Sciences, Inc. EDVA

Beverages (Production/Distribution) · IPO 2021 · data as of November 13, 2026

$0.18Market cap $2M
Open the interactive analysis →

Endovia Health Sciences, Inc. (EDVA) is a consumer staples company listed in the US with a market value of about $2M. In the twelve months to June 30, 2026 it had revenue of $32090 and net income of -$17M, a net margin of -53856.5%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -52% a year, a 5-year average ROIC of -228%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Endovia Health Sciences

Endovia Health Sciences is listed in the US and classified in beverages (production/distribution), IPO year 2021. Revenue went from $605905 in 2014 to $73066 in 2025, a decline of about 17.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 133% over three years (dilution for shareholders).

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S65.1
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)-90.9%
Revenue growth (5 yrs, per year)-52.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-7598.0%
ROIC (5-yr avg.)-228.1%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$32090$73066$801273$19M$18M$11M$3M$20387$1M$895346$1M
Net income-$17M-$25M-$24M-$21M-$22M-$29M-$29M-$5M$68206-$147534-$48846
Free cash flow——-$7M-$10M-$14M-$15M-$21M-$3M-$13241-$75872-$26311
EPS (diluted)$-6.15$-11.97$-17.68$-19.79$-23.20$-40.80$-42.40$-1.60$0.40$-0.40$0.00
Net margin-53856.5%-34537.0%-2964.8%-111.4%-119.9%-256.7%-963.6%-25191.2%5.2%-16.5%-4.8%
ROIC———-382.2%-123.5%-178.6%————-52.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Endovia Health Sciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Endovia Health Sciences pay a dividend?

Not currently.

Is Endovia Health Sciences a good stock to buy?

We do not give buy or sell advice. Endovia Health Sciences scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.